BMS Unveils Asian HCV Combo Data As China Plans Progress
This article was originally published in PharmAsia News
Executive Summary
BMS has released data from the first completed pivotal Phase III trial with an all-oral regimen for hepatitis C to have included sites in China, as it moves ahead with plans to develop the combination in this potentially large market.